Similar Items: First-Line Serplulimab versus Other Anti-PD-1/PD-L1 Antibodies Plus Chemotherapy for Esophageal Squamous Cell Carcinoma: A Systematic Review with Benefit-Risk Assessment via Matching-Adjusted Indirect Comparison
- Evaluation of plant-expressed human PD-1 as an immunogen capable of inducing native PD-1 recognizing antibodies
- Association of the PD‐L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer
- Immune escape mechanisms revealed by multifunctional nanoprobes targeting PD‐L1 in hepatic cancer progression
- Oncolytic virus and PD-1/PD-L1 blockade combination therapy
- Opposing Association of Lung Neutrophils and PD‐L1+ Monocytes in Age‐Related Severity of SARS‐CoV‐2 Infection
- Biomarker‐based long‐term safety and efficacy of PD‐1/PD‐L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis